{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:21:26Z","timestamp":1792729286183,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cell.2023.08.021","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T12:27:58Z","timestamp":1695126478000},"page":"4260-4270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":366,"title":["Alzheimer's disease: From immunotherapy to immunoprevention"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-1072","authenticated-orcid":false,"given":"Mathias","family":"Jucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lary C.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2023.08.021_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2023.08.021_bib3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.cell.2023.08.021_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.cell.2023.08.021_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of Alzheimer\u2019s disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cell.2023.08.021_bib6","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2023.08.021_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.cell.2023.08.021_bib8","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.08.021_bib9","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.1228541","article-title":"Preventing Alzheimer\u2019s disease","volume":"337","author":"Selkoe","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.cell.2023.08.021_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13024-021-00467-y","article-title":"The informed road map to prevention of Alzheimer disease: a call to arms","volume":"16","author":"McDade","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cell.2023.08.021_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature12481","article-title":"Self-propagation of pathogenic protein aggregates in neurodegenerative diseases","volume":"501","author":"Jucker","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.08.021_bib12","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","article-title":"Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases","volume":"21","author":"Jucker","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib13","doi-asserted-by":"crossref","first-page":"1255555","DOI":"10.1126\/science.1255555","article-title":"NEURODEGENERATION. Alzheimer\u2019s and Parkinson\u2019s diseases: the prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.cell.2023.08.021_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature20415","article-title":"Mammalian prions and their wider relevance in neurodegenerative diseases","volume":"539","author":"Collinge","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.08.021_bib15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature06616","article-title":"Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer\u2019s disease","volume":"451","author":"Meyer-Luehmann","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.08.021_bib16","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1126\/science.1162844","article-title":"Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer\u2019s disease","volume":"321","author":"Busche","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.cell.2023.08.021_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-05491-6","article-title":"PLD3 affects axonal spheroids and network defects in Alzheimer\u2019s disease","volume":"612","author":"Yuan","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.08.021_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid beta oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2023.08.021_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41582-022-00749-z","article-title":"Synaptic degeneration in Alzheimer disease","volume":"19","author":"Tzioras","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib21","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.neurobiolaging.2015.06.028","article-title":"Cerebral amyloid angiopathy and its co-occurrence with Alzheimer\u2019s disease and other cerebrovascular neuropathologic changes","volume":"36","author":"Brenowitz","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cell.2023.08.021_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/alz.12366","article-title":"Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis","volume":"18","author":"J\u00e4kel","year":"2022","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.cell.2023.08.021_bib114","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41593-023-01359-8","article-title":"Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)","volume":"26","author":"McKay","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2012.07.002","article-title":"Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer\u2019s disease","volume":"9","author":"Zetterberg","year":"2013","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.cell.2023.08.021_bib27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2023.08.021_bib28","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/s41467-022-34538-5","article-title":"Experimental evidence for temporal uncoupling of brain Abeta deposition and neurodegenerative sequelae","volume":"13","author":"Rother","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2023.08.021_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cell.2023.08.021_bib24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2023.08.021_bib25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cell.2023.08.021_bib29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-021-01546-6","article-title":"Current status of clinical trials on tau immunotherapies","volume":"81","author":"Ji","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cell.2023.08.021_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/1673-5374.340409","article-title":"Initial failures of anti-tau antibodies in Alzheimer\u2019s disease are reminiscent of the amyloid-beta story","volume":"18","author":"Imbimbo","year":"2023","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.cell.2023.08.021_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.08.021_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.08.021_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","article-title":"Antibodies against beta-amyloid slow cognitive decline in Alzheimer\u2019s disease","volume":"38","author":"Hock","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2023.08.021_bib35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","article-title":"Abeta species removal after abeta42 immunization","volume":"65","author":"Nicoll","year":"2006","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib36","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer\u2019s disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.08.021_bib37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.neurol.2022.06.012","article-title":"High-clearance anti-amyloid immunotherapies in Alzheimer\u2019s disease. Part 1: meta-analysis and review of efficacy and safety data, and medico-economical aspects","volume":"178","author":"Villain","year":"2022","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.cell.2023.08.021_bib38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.08.021_bib115","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/brain\/awu255","article-title":"Highly potent soluble amyloid-beta seeds in human Alzheimer brain but not cerebrospinal fluid","volume":"137","author":"Fritschi","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.08.021_bib116","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.15252\/embr.201744067","article-title":"Abeta seeding potency peaks in the early stages of cerebral beta-amyloidosis","volume":"18","author":"Ye","year":"2017","journal-title":"EMBO Rep."},{"key":"10.1016\/j.cell.2023.08.021_bib52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1126\/science.abm7285","article-title":"Cryo-EM structures of amyloid-beta 42 filaments from human brains","volume":"375","author":"Yang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.cell.2023.08.021_bib117","doi-asserted-by":"crossref","first-page":"105010","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting Abeta and tau in Alzheimer\u2019s disease","volume":"144","author":"Plotkin","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cell.2023.08.021_bib64","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41593-020-00737-w","article-title":"Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life","volume":"23","author":"Uhlmann","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib41","series-title":"Aducanumab for the TREATMENT of Alzheimer\u2019s disease","year":"2020"},{"key":"10.1016\/j.cell.2023.08.021_bib42","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","article-title":"Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases","volume":"91","author":"Bacioglu","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2023.08.021_bib44","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/brain\/awaa098","article-title":"Neurofilaments: neurobiological foundations for biomarker applications","volume":"143","author":"Gafson","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.08.021_bib45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib46","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated brain volume loss caused by anti-beta-amyloid drugs: a systematic review and meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.08.021_bib47","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1212\/WNL.0000000000207268","article-title":"Brain shrinkage in anti-beta-amyloid Alzheimer trials: neurodegeneration or pseudoatrophy?","volume":"100","author":"Barkhof","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.08.021_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/alz.13031","article-title":"Targeting amyloid beta in Alzheimer\u2019s disease: meta-analysis of low-dose solanezumab in Alzheimer\u2019s disease with mild dementia studies","author":"Holdridge","year":"2023","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.cell.2023.08.021_bib49","series-title":"Legacy of A4 secondary prevention study goes beyond negative result","year":"2023"},{"key":"10.1016\/j.cell.2023.08.021_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1750-3639.2006.tb00560.x","article-title":"Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models","volume":"16","author":"Herzig","year":"2006","journal-title":"Brain Pathol."},{"key":"10.1016\/j.cell.2023.08.021_bib51","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1038\/s41467-019-12683-8","article-title":"Cryo-EM structure and polymorphism of Abeta amyloid fibrils purified from Alzheimer\u2019s brain tissue","volume":"10","author":"Kollmer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2023.08.021_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt246","article-title":"Perspectives on future Alzheimer therapies: amyloid-beta protofibrils\u00a0\u2013 a new target for immunotherapy with BAN2401 in Alzheimer\u2019s disease","volume":"6","author":"Lannfelt","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.cell.2023.08.021_bib54","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The \u2018Arctic\u2019 APP mutation (E693G) causes Alzheimer\u2019s disease by enhanced Abeta protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00401-022-02533-1","article-title":"Cryo-EM structures of amyloid-beta filaments with the Arctic mutation (E22G) from human and mouse brains","volume":"145","author":"Yang","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2023.08.021_bib56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41594-020-0505-6","article-title":"Kinetic fingerprints differentiate the mechanisms of action of anti-Abeta antibodies","volume":"27","author":"Linse","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.cell.2023.08.021_bib57","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ajpath.2013.05.005","article-title":"Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models","volume":"183","author":"Frost","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cell.2023.08.021_bib58","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awt362","article-title":"Biochemical stages of amyloid-beta peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer\u2019s disease","volume":"137","author":"Rijal Upadhaya","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.08.021_bib59","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1093\/brain\/awac202","article-title":"Seeding, maturation and propagation of amyloid beta-peptide aggregates in Alzheimer\u2019s disease","volume":"145","author":"Li","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.08.021_bib60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41573-020-0065-9","article-title":"Leveraging preclinical models for the development of Alzheimer disease therapeutics","volume":"19","author":"Scearce-Levie","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2023.08.021_bib61","doi-asserted-by":"crossref","first-page":"e12112","DOI":"10.1002\/trc2.12112","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer's disease","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimers. Dement. (N Y)"},{"key":"10.1016\/j.cell.2023.08.021_bib62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/547153a","article-title":"Stop Alzheimer\u2019s before it starts","volume":"547","author":"McDade","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.08.021_bib63","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1523\/JNEUROSCI.4560-08.2009","article-title":"Suppression of amyloid deposition leads to long-term reductions in Alzheimer\u2019s pathologies in Tg2576 mice","volume":"29","author":"Karlnoski","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2023.08.021_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/biom12070951","article-title":"Acute effects of focused ultrasound-induced blood-brain barrier opening on anti-Pyroglu3 Abeta antibody delivery and immune responses","volume":"12","author":"Bathini","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.cell.2023.08.021_bib67","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib69","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00401-012-0943-2","article-title":"Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study","volume":"123","author":"Ikonomovic","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2023.08.021_bib70","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/WNN.0000000000000071","article-title":"Alzheimer lesions in the autopsied brains of people 30 to 50 years of age","volume":"28","author":"Pletnikova","year":"2015","journal-title":"Cogn. Behav. Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib71","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","article-title":"Temporal dynamics of beta-amyloid accumulation in aging and Alzheimer disease","volume":"96","author":"Jagust","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.08.021_bib72","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib73","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib74","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.08.021_bib75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(22)00027-8","article-title":"Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer\u2019s disease: a longitudinal observational study","volume":"21","author":"Morenas-Rodr\u00edguez","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib76","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","article-title":"CSF p-tau increase in response to Abeta-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles","volume":"143","author":"Kaeser","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2023.08.021_bib77","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2119804119","article-title":"Signatures of glial activity can be detected in the CSF proteome","volume":"119","author":"Eninger","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cell.2023.08.021_bib78","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/brain\/awad101","article-title":"Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease","volume":"146","author":"Mok","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.08.021_bib79","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib80","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies","volume":"29","author":"Okuzumi","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib81","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib82","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2214\/AJR.22.28461","article-title":"Amyloid-related imaging abnormalities: an update","volume":"220","author":"Roytman","year":"2023","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.cell.2023.08.021_bib83","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib84","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib85","series-title":"Fatal iatrogenic cerebral amyloid-related encephalitis in a patient treated with lecanemab for Alzheimer\u2019s disease: neuroimaging and neuropathology","author":"Solopova","year":"2023"},{"key":"10.1016\/j.cell.2023.08.021_bib86","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/STROKEAHA.121.036873","article-title":"Vessels sing their ARIAs: the role of vascular amyloid in the age of aducanumab","volume":"53","author":"Sveikata","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.cell.2023.08.021_bib87","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","article-title":"Cerebral hemorrhage after passive anti-Abeta immunotherapy","volume":"298","author":"Pfeifer","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.cell.2023.08.021_bib88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00401-022-02433-4","article-title":"Alzheimer disease neuropathology in a patient previously treated with aducanumab","volume":"144","author":"Plowey","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2023.08.021_bib89","doi-asserted-by":"crossref","first-page":"fcac021","DOI":"10.1093\/braincomms\/fcac021","article-title":"Histopathological correlates of haemorrhagic lesions on ex\u00a0vivo magnetic resonance imaging in immunized Alzheimer\u2019s disease cases","volume":"4","author":"Scherlek","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/j.cell.2023.08.021_bib90","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1093\/brain\/awn261","article-title":"Consequence of Abeta immunization on the vasculature of human Alzheimer\u2019s disease brain","volume":"131","author":"Boche","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.08.021_bib91","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00401-014-1340-9","article-title":"Abeta immunotherapy for Alzheimer\u2019s disease: effects on apoE and cerebral vasculopathy","volume":"128","author":"Sakai","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2023.08.021_bib92","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1523\/JNEUROSCI.21-05-01619.2001","article-title":"Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy","volume":"21","author":"Winkler","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib93","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12031-016-0804-x","article-title":"The neurobiology and age-related prevalence of the epsilon4 allele of Apolipoprotein E in Alzheimer\u2019s disease cohorts","volume":"60","author":"Heffernan","year":"2016","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib94","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/NEN.0b013e31829a25b9","article-title":"APOE-epsilon2 and APOE-epsilon4 correlate with increased amyloid accumulation in cerebral vasculature","volume":"72","author":"Nelson","year":"2013","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib95","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11910-022-01235-1","article-title":"Vascular considerations for amyloid immunotherapy","volume":"22","author":"Foley","year":"2022","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.cell.2023.08.021_bib96","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S1474-4422(22)00208-3","article-title":"The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study","volume":"21","author":"Charidimou","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41586-022-05440-3","article-title":"Medin co-aggregates with vascular amyloid-beta in Alzheimer\u2019s disease","volume":"612","author":"Wagner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.08.021_bib98","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1474-4422(18)30318-1","article-title":"The glymphatic pathway in neurological disorders","volume":"17","author":"Rasmussen","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib99","doi-asserted-by":"crossref","first-page":"611485","DOI":"10.3389\/fneur.2020.611485","article-title":"Cerebral vessels: an overview of anatomy, physiology, and role in the drainage of fluids and solutes","volume":"11","author":"Agarwal","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.cell.2023.08.021_bib100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-022-05397-3","article-title":"Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid","volume":"611","author":"Drieu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.08.021_bib101","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-022-05474-7","article-title":"Brain borders at the central stage of neuroimmunology","volume":"612","author":"Rustenhoven","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.08.021_bib102","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.cell.2023.08.021_bib103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13195-023-01196-8","article-title":"Cerebral A\u03b2 deposition precedes reduced cerebrospinal fluid and serum A\u03b242\/A\u03b240 ratios in the AppNL-F\/NL-F knock-in mouse model of Alzheimer\u2019s disease","volume":"15","author":"Andersson","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.cell.2023.08.021_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd7522","article-title":"APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function","volume":"13","author":"Xiong","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib105","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41593-023-01352-1","article-title":"\u03b22-Microglobulin coaggregates with Abeta and contributes to amyloid pathology and cognitive deficits in Alzheimer\u2019s disease model mice","volume":"26","author":"Zhao","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib106","doi-asserted-by":"crossref","first-page":"e11227","DOI":"10.15252\/emmm.201911227","article-title":"Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region","volume":"12","author":"Schlepckow","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib107","doi-asserted-by":"crossref","first-page":"eabq0095","DOI":"10.1126\/scitranslmed.abq0095","article-title":"A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer\u2019s disease","volume":"14","author":"Zhao","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2023.08.021_bib108","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neuron.2014.12.064","article-title":"Immunotherapeutic approaches for Alzheimer\u2019s disease","volume":"85","author":"Wisniewski","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2023.08.021_bib109","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nrn938","article-title":"Amyloid-beta immunotherapy for Alzheimer\u2019s disease: the end of the beginning","volume":"3","author":"Schenk","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cell.2023.08.021_bib110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt237","article-title":"Active immunotherapy options for Alzheimer\u2019s disease","volume":"6","author":"Winblad","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.cell.2023.08.021_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043895","article-title":"Alzheimer\u2019s disease: a brief history of immunotherapies targeting amyloid \u03b2","volume":"24","author":"Vogt","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cell.2023.08.021_bib112","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/brain\/awab092","article-title":"To what degree is late life cognitive decline driven by age-related neuropathologies?","volume":"144","author":"Boyle","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.08.021_bib113","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867423009108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867423009108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:08:18Z","timestamp":1758802098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867423009108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":117,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0092867423009108"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2023.08.021","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer's disease: From immunotherapy to immunoprevention","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2023.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}